Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women’s health initiative randomized trials
Margaret S. Pichardo, Aaron K. Aragaki, JoAnn E. Manson, Kathy Pan, Su Yon Jung, Thomas E. Rohan, Reed Mszar, Rowan T. Chlebowski · 2026
Read Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women’s health initiative randomized trials by Margaret S. Pichardo, Aaron K. Aragaki, JoAnn E. Manson, Kathy Pan, Su Yon Jung, Thomas E. Rohan, Reed Mszar, Rowan T. Chlebowski (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13599497.txt.
Description
Margaret Pichardo and seven co-authors report nearly 24 years of follow-up on hormone therapy and liver cancer in a 2026 paper. The data come from two large randomized trials of the Women's Health Initiative.
One trial gave estrogen plus a progestin to 16,608 women with a uterus; the other gave estrogen alone to 10,739 women after hysterectomy. Only 74 liver cancers appeared in all that time. Neither treatment changed the overall rate of the cancer or deaths from it. One caution surfaced: women in their fifties on the combined therapy, and past users of birth control pills, showed higher rates in subgroups. The authors call the main answer reassuring, with a flag for more study.
Catalog record
| CREATOR | Margaret S. Pichardo, Aaron K. Aragaki, JoAnn E. Manson, Kathy Pan, Su Yon Jung, Thomas E. Rohan, Reed Mszar, Rowan T. Chlebowski |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |